Table 2.
Pharmacological treatment of the participants categorized according to KDIGO stages of chronic kidney disease.
| Variable | G1 (n = 185) | G2 (n = 96) | G3a (n = 30) | G3b (n = 23) | G4 (n = 24) | G5 (n = 24) | p |
|---|---|---|---|---|---|---|---|
| Metformin (%) | 94.9 | 94.4 | 70.0 a | 31.8a,b,c | 17.4a,b,c | 4.5a,b,c,d | <0.001 |
| Insulin treatment (%) | 22.8 | 20.3 | 44.4a,b | 77.3 | 69.6a,b | 81.8a,b,c | <0.001 |
| Sulfonylureas (%) | 25.4 | 16.7 | 25.0 | 9.1 | 13.0 | 9.1 | 0.352 |
| DPP4 inhibitors (%) | 3.4 | 0.0 | 5.0 | 13.6 | 13.0 | 4.5 | 0.289 |
| Statins (%) | 28.8 | 61.1 a | 50.0 | 54.5 a | 47.8 | 45.5 | 0.105 |
| Fibrates (%) | 15.3 | 33.3 | 25.0 | 31.8 | 39.1 a | 4.5b,d,e | 0.037 |
| ACEI (%) | 18.6 | 33.3 | 35.0 | 36.4 | 26.1 | 18.2 | 0.420 |
| ARB (%) | 8.5 | 22.2 | 10.0 | 40.9 a | 30.4 a | 45.5a,c | 0.001 |
Variables are shown as percentages. p value: chi2.
a
p < 0.05 versus G1.
b
p < 0.05 versus G2.
c
p < 0.05 versus G3a.
d
p < 0.05 versus G3b.
e
p < 0.05 versus G4.
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; DPP4, dipeptidyl peptidase-4 inhibitors.